TrialLancet (London, England)2020

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia.

Denis Y Logunov et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.